SavedAdd your journal

Journals / Güncel Retina Dergisi / 2021 / Cilt: 5 - Sayı: 2

Treatments Being Developed in Retinitis Pigmentosa

Retinitis Pigmentosada Geliştirilmekte Olan Tedaviler

Mahmut KAYA
Ferit Hakan ÖNER
Pages
150–154
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

New or experimental approaches for treatment of RP include platelet-rich plasma, gene therapy, transplantation of fetal retinal cells or stem cells, and electronic retinal prostheses.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Recent developments in understanding the pathophysiology of retinitis pigmentosa (RP) have shown that there have been new hopes in the treatment of this disease which can cause severe vision loss.
📊
Key Findings & Data:Proven therapy for RP-associated photoreceptor loss and retinal pigment epithelial damage has not yet been reported.
💡
Conclusion & Impact:New or experimental approaches for treatment of RP include platelet-rich plasma, gene therapy, transplantation of fetal retinal cells or stem cells, and electronic retinal prostheses.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Recent developments in understanding the pathophysiology of retinitis pigmentosa (RP) have shown that there have been new hopes in the treatment of this disease which can cause severe vision loss. Proven therapy for RP-associated photoreceptor loss and retinal pigment epithelial damage has not yet been reported. New or experimental approaches for treatment of RP include platelet-rich plasma, gene therapy, transplantation of fetal retinal cells or stem cells, and electronic retinal prostheses.

Özet

Retinitis pigmentosa (RP)’nin patofizyolojisinin daha iyi anlaşılmasındaki gelişmeler, ciddi görme kaybı ile sonuçlanan bu hastalığın tedavisinde yeni umutlar vadetmektedir. RP ile ilişkili fotoreseptör kaybı ve retina pigment epitel hasarı için etkinliği kanıtlanmış tedavi halen mevcut değildir. RP’nin tedavisinde yeni veya deneysel yaklaşımlar arasında trombositten zengin plazma, gen tedavisi, fetal retina hücreler veya kök hücre transplantasyonu ve elektronik retinal protezler bulunmaktadır.

🔖

Cite This Article

KAYA, M., ÖNER, F. H. (2021). Treatments Being Developed in Retinitis Pigmentosa. Güncel Retina Dergisi, Cilt: 5 - Sayı: 2, 150–154. https://ajindex.com/articles/224226

References (13)

  1. Retinitis pigmentosa. A symposium on terminology and methods of examination. Ophthalmology. 1983;90(2):126-131. Berson EL. Retinitis pigmentosa. The Friedenwald Lecture. Invest Ophthalmol Vis Sci. 1993;34(5):1659-1676.
  2. Chang GQ, Hao Y, Wong F. Apoptosis: final common pathwayof photoreceptor death in rd, rds, and rhodopsin mutant mice. Neuron. 1993:11(4);595–605.
  3. Tso MO, Zhang C, Abler AS, Chang CJ, Wong F, Chang GQ, et al. Apoptosis leads to photoreceptor degeneration in inherited retinal dystrophy of RCS rats. Invest Ophthalmol Vis Sci. 1994:35(6);2693–2699.
  4. Jayakody SA, Gonzalez-Cordero A, Ali RR, Pearson RA. Cellular strategies for retinal repair by photoreceptor replacement. Prog Retin Eye Res. 2015:46;31–66.
  5. Cuenca N, Fernandez-Sanchez L, Campello L, Maneu V, De la Villa P, Lax P, et al. Cellular responses following retinal injuries and therapeutic approaches for neurodegenerative diseases. Prog Retin Eye Res. 2014:43;17–75.
  6. Sahel JA, Roska B. Gene therapy for blindness. Annu Rev Neurosci. 2013;36:467-88.
  7. Birch DG, Bennett LD, Duncan JL, Weleber RG, Pennesi ME. Long-term follow-up of patients with retinitis pigmentosa receiving intraocular ciliary neurotrophic factor implants. Am J Ophthalmol. 2016;170:10-14.
  8. Guadagni V, Novelli E, Piano I, Gargini C, Strettoi E. Pharmacological approaches to retinitis pigmentosa: a laboratory perspective. Prog Retin Eye Res. 2015:48;62–81.
  9. Murase H, Tsuruma K, Shimazawa M, Hara H. TUDCA promotes phagocytosis by retinal pigment epithelium via MerTK activation. Invest Ophthalmol Vis Sci. 2015;56(4):2511-2518.
  10. Hodge WG, Barnes D, Schachter HM, Pan YI, Lowcock EC, Zhang Y, et al. The evidence for efficacy of omega-3 fatty acids in preventing or slowing the progression of retinitis pigmentosa: a systematic review. Can J Ophthalmol. 2006;41(4):481-490.
  11. Hoffman DR, Locke KG, Wheaton DH, Fish GE, Spencer R, Birch DG. A randomized, placebo-controlled clinical trial of docosahexaenoic acid supplementation for X-linked retinitis pigmentosa. Am J Ophthalmol. 2004;137(4):704-718.
  12. Greenstein VC, Holopigian K, Siderides E, Seiple W, Carr RE. The effects of acetazolamide on visual function in retinitis pigmentosa. Invest Ophthalmol Vis Sci 1993;34(1):269-273.
  13. Fishman GA, Apushkin MA. Continued use of dorzolamide for the treatment of cystoid macular oedema in patients with retinitis pigmentosa. Br J Ophthalmol. 2007;91(6):743-745. Arslan U. Management of cystoid macular edema secondary to retinitis pigmentosa via subliminal micropuls